Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04330534 | First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH | PHASE1 | COMPLETED | 168 | — | — | Mar 3, 2020 | Jan 25, 2021 | Feb 17, 2022 | 4 | Austria, South Africa +1 |
| Arm | Type | Description |
|---|---|---|
| BCX9930 | EXPERIMENTAL | Parts 1, 2 and 3 |
| Placebo | PLACEBO_COMPARATOR | Parts 1 and 2 only |
| Name | Type | Description |
|---|---|---|
| BCX9930 | DRUG | BCX9930 capsules for oral administration |
| Placebo | DRUG | placebo to match BCX9930 capsules for oral administration |
Key Inclusion Criteria (Parts 1, 2, and 3): * Able to provide written informed consent * Acceptable birth control measures for male subjects and women of childbearing potential * Is expected to adequately comply with required study procedures and restrictions Key Inclusion Criteria (Parts 1 and 2)...